BSFA Stock Overview
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ANI Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$53.50 |
| 52 Week High | US$64.00 |
| 52 Week Low | US$44.20 |
| Beta | 0.71 |
| 11 Month Change | 0% |
| 3 Month Change | -4.46% |
| 1 Year Change | 14.81% |
| 33 Year Change | 51.99% |
| 5 Year Change | -1.83% |
| Change since IPO | 1,027.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| BSFA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.9% | -1.2% | -0.02% |
| 1Y | 14.8% | -20.1% | 8.2% |
Return vs Industry: BSFA exceeded the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: BSFA exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| BSFA volatility | |
|---|---|
| BSFA Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: BSFA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BSFA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 642 | Nikhil Lalwani | www.anipharmaceuticals.com |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals.
ANI Pharmaceuticals, Inc. Fundamentals Summary
| BSFA fundamental statistics | |
|---|---|
| Market cap | €1.07b |
| Earnings (TTM) | -€8.42m |
| Revenue (TTM) | €533.40m |
2.0x
P/S Ratio-126.8x
P/E RatioIs BSFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSFA income statement (TTM) | |
|---|---|
| Revenue | US$555.46m |
| Cost of Revenue | US$223.35m |
| Gross Profit | US$332.11m |
| Other Expenses | US$340.87m |
| Earnings | -US$8.77m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 59.79% |
| Net Profit Margin | -1.58% |
| Debt/Equity Ratio | 145.2% |
How did BSFA perform over the long term?
See historical performance and comparison